- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02354118
Maintaining Patency in Implanted Port Catheters
September 15, 2022 updated by: Rachel Baker, TriHealth Inc.
Maintaining Patency in Implanted Port Catheters With Saline Only Flushes
The purpose of this study is to determine the safest and most effective flushing solution for maintaining patency (unobstructed flow) in implanted port catheters.
The complication rate in patients whose ports are flushed with saline only will be compared to the complication rate in patients whose ports are flushed with a combination of saline and heparinized saline.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to determine the safest and most effective flushing solution for maintaining patency (unobstructed flow) in implanted port catheters.
The complication rate in patients whose ports are flushed with saline only will be compared to the complication rate in patients whose ports are flushed with a combination of saline and heparinized saline.
These complications include partial or complete obstruction, infection of the central line, and/or the onset of heparin induced thrombocytopenia.
Study Type
Interventional
Enrollment (Actual)
436
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45220
- TriHealth Cancer Institute Good Samaritan Infusion Center at GSH
-
Cincinnati, Ohio, United States, 45242
- Ambulatory Treatment Center at Bethesda North TriHealth Hospital
-
Cincinnati, Ohio, United States, 45242
- TriHealth Cancer Institute Good Samaritan Infusion Center, Medicenter
-
Cincinnati, Ohio, United States, 45247
- TriHealth Cancer Institute Good Samaritan Infusion Center, Cheviot
-
Cincinnati, Ohio, United States, 45255
- TriHealth Cancer Institute Good Samaritan Infusion Center, Anderson
-
Cincinnati, Ohio, United States, 45219
- UC Health Barrett Infusion Center
-
Hamilton, Ohio, United States, 45011
- TriHealth Cancer Institute Good Samaritan Infusion Center Butler County
-
Oxford, Ohio, United States, 45056
- McCullough Hyde Memorial Hospital Infusion Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Able to read and understand English
- Has an implanted port in place less than one (1) year
- Evidence of a patent (unobstructed) port catheter prior to enrollment in the study
- Is receiving active treatment (i.e., receiving a therapeutic drug through the implanted port)
- Current treatment protocol projected to continue for a minimum of three (3) months
- Anticipates receiving care at the identified centers for 12 months following enrollment in the study
- Does not receive care of implanted port at any other facility
Exclusion Criteria:
- Has documented heparin platelet antibody (i.e., could not be randomized to either group) or other allergy to heparin
- Receiving therapeutic dose of an anticoagulant (e.g.,warfarin, heparin, enoxaparin)
- Does not have a BioFlo port (heparinized port)
- Does not meet one or more of the inclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control Group
Heparinized saline catheter flush - The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
|
The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
|
|
Experimental: Intervention Group
Saline-only catheter flush - The intervention group will have their port catheters flushed with saline only.
|
The intervention group will have their port catheters flushed with saline only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With First Complete Occlusion Within 1 Year
Time Frame: baseline to 1 year
|
Number of participants who had a first complete occlusion (Blockage) within 1 year
|
baseline to 1 year
|
|
Number of Participants With First Partial Occlusion Within 1 Year
Time Frame: baseline to 1 year
|
Number of Participants with First Partial Occlusion (Blockage) within 1 year
|
baseline to 1 year
|
|
Number of Participants With First Cathflo Administration for Occlusion (Blockage) Within 1 Year
Time Frame: baseline to 1 year
|
Number of Participants with First Cathflo administration for Occlusion (Blockage) within 1 year
|
baseline to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With First Complete or Partial Occlusion Within 1 Year
Time Frame: baseline to 1 year
|
Number of Participants with either a First Complete or Partial Occlusion (Blockage) within 1 year
|
baseline to 1 year
|
|
Number of Participants With HIT Within 1 Year
Time Frame: baseline to 1 year
|
Heparin Induced Thrombocytopenia (HIT) as measured by a positive HIT antibody test, or any other heparin allergy, will be recorded.
|
baseline to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sarah Pelgen, BSN, RN, OCN, TriHealth Cancer Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2013
Primary Completion (Actual)
December 11, 2021
Study Completion (Actual)
December 17, 2021
Study Registration Dates
First Submitted
January 29, 2015
First Submitted That Met QC Criteria
January 29, 2015
First Posted (Estimate)
February 3, 2015
Study Record Updates
Last Update Posted (Actual)
October 12, 2022
Last Update Submitted That Met QC Criteria
September 15, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Other Study ID Numbers
- 12135-12-079
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.